Browse Category

NYSE:PFE 1 October 2025 - 4 November 2025

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Pfizer Shares Offer 6.4% Yield, Surpassing Wall Street Optimism After Results
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alonereuters.comreuters.com. The share price is now hovering in the low $70sreuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emergedprnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4reuters.com – reflecting hundreds of percent in gains for early investors.
4 November 2025
···
Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week rangemarketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s following its government pricing deal announcementmarketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However, disappointing industry news and the uncertainty of the Metsera takeover battle led to profit-taking. By early November, Pfizer’s 50-day average converged with its 200-day averagemarketbeat.com, indicating a lack of a strong trend. This technical “flatline” suggests the stock is searching for direction, consolidating after its volatile swings.
4 November 2025
·····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market sharereuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performancereuters.comreuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal”reuters.com. This was weeks after Novo’s top shareholder overhauled its board to demand a faster turnaround in the weight-loss arenareuters.comreuters.com.
4 November 2025
···
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensusreuters.com. This was achieved on quarterly revenue of about $16.7 billion, which, while ~6% lower than the same period last year, slightly exceeded analysts’ forecastsstocktwits.comreuters.com. The decline was largely anticipated due to the sharp drop in COVID-19 product demand, but stronger-than-expected sales in other areas helped Pfizer beat the Street’s estimates.
4 November 2025
···
AI Rally Hits Speed Bump as Futures Fall – Key Facts Before the Nov. 4 Market Open

AI Rally Hits Speed Bump as Futures Fall – Key Facts Before the Nov. 4 Market Open

Stock index futures are firmly in the red before the opening bell, indicating Wall Street will give back some of Monday’s gains. S&P 500 futures are down roughly 0.9% and Nasdaq 100 futures off 1.2%, with Dow futures –0.7%seekingalpha.comseekingalpha.com. This comes after the Nasdaq Composite and S&P 500 ticked higher yesterday, buoyed by excitement over a big Amazon–OpenAI AI partnership, even as the Dow slippedeconomictimes.indiatimes.com. That optimism has proved short-lived; by early Tuesday, futures reversed as investors refocus on stretched valuations in the tech sector and worry that the AI boom may have overshot fundamentalsswissinfo.chswissinfo.ch.
4 November 2025
···········
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peaksharewise.com. In the past three years, the shares have tumbled about 50% as the company’s COVID-fueled revenue boom faded and investors braced for patent expirationssharewise.com. By mid-2025, Pfizer traded near multi-year lows, though it bounced off those lows in early October after positive news on earnings and policy. Notably, Pfizer’s stock surged ~15% at the end of Q3 when it announced the drug pricing agreement and broader market sentiment toward pharma improved. However, renewed concerns – including a light prescription uptake for the latest COVID booster and uncertainty around Q3 earnings – saw the stock drift back to the mid-$24 range by early Novemberstatmuse.comstatmuse.com.
3 November 2025
··
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Founded in 1849, Pfizer Inc. has grown into a pillar of the pharmaceutical industry, known for landmark drugs and vaccines. From breakthrough treatments like Lipitor and Viagra, to its 2020 partnership with BioNTech delivering the first approved COVID-19 vaccine, Pfizer’s innovations have had global impact. Today the company employs about 81,000 people worldwide and operates 35+ manufacturing sitesxtalks.com. It was the world’s top drugmaker by sales during the pandemic boom, and even with post-COVID declines Pfizer is expected to generate ~$62 billion in revenue in 2025 – underscoring its massive scalets2.tech.
2 November 2025
·
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43ts2.tech, and the late-September rally stalled out near the upper-$20s – a zone that now acts as an overhead resistance. Notably, PFE is trading below its 200-day moving average, indicating lingering bearish momentumtrefis.com. On the upside, a decisive push above the $27–$28 level would be a bullish signal that the stock’s trend is turning. In the near term, the stock has managed to climb back above its 50-day moving averageinvesting.com, a positive sign, and appears to have technical support in the mid-$24 areachartmill.com. Chart indicators are mixed: Pfizer’s RSI sits around 48, smack in neutral territorychartmill.com, and its MACD momentum indicator is slightly negativechartmill.com. This suggests the stock is neither overbought nor oversold at current levels, but hasn’t yet gathered strong upward momentum. Traders may watch $23–$24 as a support zone – if PFE falls below that, it could retest the year’s low near $21. Conversely, $27 is key resistance – a breakout above that could open the door to the low-$30s. In summary, Pfizer’s chart is still repairing: the
1 November 2025
··
Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior bidreuters.com. This move comes just days after the foundation coup at Novoreuters.com, signaling a full-aggression strategy. Metsera confirmed the offer is “superior” to Pfizer’s, giving Pfizer four business days to respondts2.tech. Pfizer CEO Albert Bourla has publicly talked up this obesity play, so Pfizer is not likely to concede easily. Unsurprisingly, Pfizer immediately denounced Novo’s counterbid as “reckless” and vowed to defend the original agreementreuters.com. Observers note Novo carefully included the contingent CVRs and claims it adhered to the “no raid” clause in its agreement with Pfizerreuters.com, so the fight may end up in arbitration if no private settlement is reached.
31 October 2025
····
Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer’s stock has been rangebound in the low-to-mid $20s for much of 2025. By late September, PFE traded around $23.60 – about 9% below its price a year earlierts2.tech – as investors grappled with the end of Covid vaccine and treatment revenues. That all changed in early October. In the final trading week of September, Pfizer shares jumped ~15%, rallying from roughly $23.6 to about $27.2 by Oct. 1ts2.tech. This dramatic move was largely driven by two key announcements and marked one of PFE’s strongest weekly gains in years.
30 October 2025
··
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash plus up to $22.50 in contingent paymentssec.gov. Pfizer CEO Albert Bourla said this deal “propels Pfizer into this key therapeutic area” of obesity treatmentsec.gov. Metsera CEO Whit Bernard called the deal “an excellent outcome for our shareholders” and praised the chance to “realize the promise of improved human health at scale” under Pfizer’s wingsec.gov.
30 October 2025
····
Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolioreuters.com. According to MarketScreener, the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRsmarketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront plus CVRs, for up to ~$7.3Bts2.techreuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts.
30 October 2025
····
Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

Pfizer’s stock has endured a rough 2025, trading in the low-to-mid $20s for much of the year and touching multi-year lows. By late September, PFE was around $23.60 – down ~9% year-to-date and ~18% from a year priorts2.tech. It languished near the bottom of its 52-week rangets2.tech as the company faced a post-pandemic hangover: revenues from its COVID-19 vaccine and pill plummeted from $37.8B in 2022 to about $12.5B in 2024ts2.tech. Wall Street projected Pfizer’s EPS would fall by more than half from 2022 to 2025ts2.tech, reflecting this “COVID cliff” in sales and ongoing patent cliffs ahead. These factors, along with drug pricing worries, weighed heavily on investor sentiment through Q3 2025.
27 October 2025
··
Wall Street Explodes: Dow Jones Jumps 400 Points as Inflation Cools – Tech Stocks Lead, Fed Cuts Expected

Wall Street Explodes: Dow Jones Jumps 400 Points as Inflation Cools – Tech Stocks Lead, Fed Cuts Expected

Friday’s broad rally sent all major U.S. indexes to fresh highs. The Dow’s 400‑point gain topped the largest single‑day jump of 2025, while the S&P 500 and Nasdaq also closed at record levelseconomictimes.indiatimes.com. Market leadership was clear: technology and semiconductor firms outperformed. For example, Advanced Micro Devices surged 6.5% and Nvidia 4.2% on Fridayeconomictimes.indiatimes.com. These gains reflect strong demand for AI and cloud computing products, as well as better-than-expected earnings in the sector.
24 October 2025
·············
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Before the late-September rally, Pfizer’s stock had been trading lethargically. As one analysis notes, PFE closed around $23.60 on Sept. 26, roughly flat for the year and down ~9% since January ts2.tech. Over the prior 12 months it had fallen about 18%, weighed down by fading COVID sales and patent losses ts2.tech. Its 52-week range was about $20.9–$30.4 ts2.tech, so the recent surge took it to the upper end of that range.
19 October 2025
·
Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

After a roller-coaster week, the Nasdaq Composite Index managed to finish in positive territory, showcasing resilience in the face of multiple risk flare-ups. The index closed Friday at 22,679.98 points, up 117.44 points on the dayreuters.com. All three major U.S. indices posted weekly gains, even as intraday swings tested investors’ nerves. The tech-heavy Nasdaq remains within striking distance of its record high set earlier this month, and is up roughly 15–17% for the year to datets2.tech – a strong performance reflecting 2025’s bullish momentum.
18 October 2025
·········
Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a post-pandemic hangover. As of Sept 25, the stock was down roughly 9% year-to-date and about 18% below its level one year priorts2.tech. It traded near the bottom of its 52-week range, weighed down by steep declines in COVID vaccine and pill sales and general pessimism on its growth prospectsts2.techts2.tech. In fact, Pfizer’s COVID-driven revenues had plummeted from $37.8 billion in 2022 to an estimated $12.5 B in 2024, creating a “COVID cliff” that halved earnings and soured the stock’s appealts2.tech. The result: Pfizer – once a market darling – became an underperformer in 2023–25, even as the broader S&P 500 rose modestly and other big pharma names held steadierts2.tech.
6 October 2025
·
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Lara Castleton of Janus Henderson noted that Tuesday’s White House–Pfizer announcement “was the catalyst for healthcare,” freeing up investors to rotate into the beaten-down sector reuters.com. Kyle Rodda at Capital.com observed that the weak ADP report “suggests the U.S. economy is in almost dire need for further policy support,” so markets are pricing in much higher odds of Fed rate cuts in October and December reuters.com. He added that “after some initial jitters, markets shrugged off the U.S. government shutdown, at least for now,” since past shutdowns have had “trivial” market impact reuters.com.
2 October 2025
······
Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

In early September 2025, Pfizer was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring ~6.8% that day investing.com. The rally continued on Oct. 1, with PFE closing at $27.21 investing.com. In total, Pfizer climbed roughly 15% in the five trading days Sept 26–Oct 1. By contrast, Pfizer had been about flat in August–September, hovering in the low $24s prior to this surge. The late-month gains reflect investor excitement over the Trump pricing deal and positive news on the pipeline.
2 October 2025
···
1 … 9 10 11 12
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Constellation Energy

NASDAQ: CEG 94 / 100
#3 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 92 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

AIG

NYSE: AIG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.